Top 5 Electric Utility Stocks To Buy For 2015

One of my favorite sectors is just starting to make gains… I expect much more to come…   Three months ago, I told you to buy semiconductor stocks. These companies make the "chips" that go into computers, smartphones, video-game consoles, and other electronic devices.   They were one of the few great "bargains" left in the stock market. And they had a big-picture tailwind working in their favor. So I recommended taking a position.   If you followed that advice, you're likely sitting on profits today. Even better, this sector is still cheap and has huge upside potential. Let me explain…   As I told you in March, chip stocks have spent the past two years drastically underperforming the S&P 500.   Most of the weakness was due to a massive drop in personal computer (PC) sales. Despite the growth in sales of tablets – like Apple's iPad and Microsoft's Surface – the PC slowdown left most chip companies stuck with inflated inventory levels.

Top 5 Electric Utility Stocks To Buy For 2015: NewLink Genetics Corp (NLNK)

NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (Hy perAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.

The Company’s HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system’s tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.

HyperAcute Cancer Immunotherapy Product Candidates

In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.

HyperAcute Cancer Immunotherapy Technology

The Company’s HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.

IDO Pathway Inhibitor Product Candidate

The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    In trading on Thursday, healthcare shares were relative laggards, down on the day by about 0.64 percent. Top decliners in the sector included Sunesis Pharmaceuticals (NASDAQ: SNSS), off 5.6 percent, and NewLink Genetics (NASDAQ: NLNK), down 6.3 percent.

  • [By Jayson Derrick]

    NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and “gathering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.” Shares fell 16.20 percent, closing at $31.60.

Top 5 Electric Utility Stocks To Buy For 2015: NanoViricides Inc (NNVC)

NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patien ts; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide – I against HIV/AIDS; HerpeCide – I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc’s Inno-Haven LLC acquired a light industrial building.

The Company’s product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD’s) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses – epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.

The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide agai nst adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.

The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.

Advisors’ Opinion:

  • [By Roberto Pedone]

    One under-$10 nano-biopharmaceutical player that’s starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.

    If you take a look at the chart for Nanoviricides, you’ll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.

    Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday’s high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.

    Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 5 Electric Utility Stocks To Buy For 2015: Hubbell Inc (HUBB)

Hubbell Incorporated (Hubbell), incorporated in 1905, is engaged in the design, manufacture and sale of electrical and electronic products for a range of non-residential and residential construction, industrial and utility applications. Products are either sourced complete, manufactured or assembled by subsidiaries in the United States, Canada, Switzerland, Puerto Rico, Mexico, the People’s Republic of China, Italy, the United Kingdom, Brazil and Australia. Hubbell also participates in joint ventures in Taiwan, Hong Kong, and maintains sales offices in Singapore, China, Mexico, South Korea and countries in the Middle East. It operates in two segments: Electrical segment and the Power segment. The Electrical segment consists of electrical systems products and lighting products. During the year ended December 31, 2011, it acquired two product lines. The first product line acquired consists of grounding, bonding and cable management solutions with renewable energy applicati ons, while the second product line consists of fire pump control panels. The Company has several operations located outside of the United States. These operations manufacture, assemble and/or market Hubbell products and service both the Electrical and Power segments.

Electrical Segment

The Electrical segment consists of businesses that sell stock and custom products, including standard and special application wiring device products, rough-in electrical products, connector and grounding products, lighting fixtures and controls, as well as other electrical equipment. The products are used in and around industrial, commercial and institutional facilities by electrical contractors, maintenance personnel, electricians and telecommunications companies. In addition, certain businesses design and manufacture a variety of high voltage test and measurement equipment, industrial controls and communication systems used in the non-residential and industrial mark ets. Many of these products are designed such that they can ! also be used in harsh and hazardous locations where a potential for fire and explosion exists due to the presence of flammable gasses and vapors. Harsh and hazardous products are primarily used in the oil and gas (onshore and offshore) and mining industries. Certain lighting fixtures, wiring devices and electrical products also have residential and utility applications.

These products are primarily sold through electrical and industrial distributors, home centers, retail and hardware outlets, and lighting showrooms. Special application products are sold primarily through wholesale distributors to contractors, industrial customers and original equipment manufacturers (OEMs). High voltage products are sold primarily by direct sales to customers through its sales engineers. Hubbell maintains a sales and marketing organization to assist users with the application of certain products to their specific requirements, and with architects, engineers, industrial designers , OEMs and electrical contractors for the design of electrical systems to meet the specific requirements of industrial, non-residential and residential users. Hubbell is also represented by sales agents for its lighting fixtures and controls, electrical wiring devices, rough-in electrical products and high voltage products lines.

Hubbell designs, manufactures and sells thousands of wiring and electrical products, which are supplied principally to industrial, non-residential and residential customers. These products include cable reels, cable glands and fittings, connectors and tooling, floor boxes, ground fault devices, wiring devices and accessories, switches and dimmers, pin and sleeve devices, electrical motor controls, and steel and plastic electrical enclosures. Its products also include junction boxes, plugs and receptacles, datacom connectivity and enclosures, speciality communications equipment high voltage test systems and mining communication and contr ols. These wiring and electrical products are sold under var! ious bran! ds and/or trademarks, including Hubbell, Kellems, Bryant, Burndy, Wejtap, Implo, Raco, Bell, Wiegmann, Killark, Hawke, Chalmit, Victor, GAI-Tronics, Gleason Reel, Haefely, Hipotronics and Austdac.

Hubbell manufactures and sells lighting fixtures and controls for indoor and outdoor applications. The markets served include residential, commercial, institutional and industrial. The Company has a range of light emitting diode (LED)-luminaire products within its portfolio. Hubbell’s variety of lighting products includes canopy light fixtures, emergency lighting/exit signs, specification grade LED fixtures, floodlights and poles, recessed, surface mounted and track fixtures, parking lot/parking garage fixtures, bollards, and bath/vanity fixtures and fans. Its products also include chandeliers, sconces, directionals, fixtures used to illuminate athletic/recreational fields, decorative landscaping fixtures, flourescent fixtures, ceiling fans, site and area lighting fi xtures, and occupancy, dimming and daylight harvesting sensors.

These lighting products are sold under various brands and/or trademarks, including Kim Lighting, Sportsliter Solutions, Kurt Versen, Beacon Products, Architectural Area Lighting, Security Lighting Systems, Sterner Lighting, Prescolite, Precision-Paragon [P2], Hubbell Building Automation, Spaulding Lighting and Alera Lighting. Brands and/or trademarks also include Dual-Lite, Progress Lighting and Hubbell Outdoor Lighting.

Power Segment

The Power segment consists of operations that design and manufacture various distribution, transmission, substation and telecommunications products primarily used by the electrical utility industry. In addition, certain of these products are used in the civil construction and transportation industries. Products are sold to distributors and directly to users, such as electric utilities, telecommunication companies, pipeline and mining operation s, industrial firms, construction and engineering firms. Pro! ducts inc! lude Arresters, Cutouts and fuse links, lineman tools, hoses and gloves, overhead and pad mounted switches, high voltage bushings, insulators, cable terminations and accessories, formed wire products and splices, taps and connectors. Its products also include grounding equipment, programmable reclosures, sectionalizers, pole line hardware and polymer concrete and fiberglass enclosures and equipment pads.

These products are sold under various brands and/or trademarks, including Ohio Brass, Fargo, Quazite, Electro Composites, Hot Box, Chance, Hubbell, Quadri*sil, USCO, PCORE and Anderson. Brands and/or trademarks also include Polycast, Comcore, CDR and Delmar.

Advisors’ Opinion:

  • [By Seth Jayson]

    Hubbell (NYSE: HUBB  ) reported earnings on April 19. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q1), Hubbell met expectations on revenues and met expectations on earnings per share.

  • [By Seth Jayson]

    Hubbell (NYSE: HUBB  ) reported earnings on July 18. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended June 30 (Q2), Hubbell met expectations on revenues and beat expectations on earnings per share.

Top 5 Electric Utility Stocks To Buy For 2015: Novartis AG (NOVN)

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. It has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. In February 2014, it acquired CoStim Pharmaceuticals, Inc. Advisors’ Opinion:

  • [By Corinne Gretler]

    Novartis AG (NOVN) climbed 2 percent to 69.25 Swiss francs after raising its full-year forecasts. Sales will increase at a low-to mid-single-digit percentage rate in constant currencies, and core operating income will match or exceed the previous year, Europe’s biggest drugmaker said. In July, the company forecast a low-single-digit percentage decline in earnings in 2013, with sales rising at a similar rate.

  • [By Sofia Horta e Costa]

    Novartis AG (NOVN) slipped 1.3 percent to 67.20 Swiss francs after JPMorgan Chase cut its recommendation on the drugmaker to neutral from overweight, a rating similar to buy. The stock has rallied 17 percent so far this year, compared with a 15 percent increase for the Swiss Market Index.

  • [By Corinne Gretler]

    Novartis AG (NOVN) climbed 1.3 percent after saying a psoriasis treatment met all its objectives in a clinical study. Lloyds (LLOY) Banking Group Plc advanced 3.8 percent after a person with knowledge of the matter said a former Standard Chartered Plc executive may mount a bid for a stake in the U.K.’s biggest mortgage lender. TGS Nopec Geophysical ASA declined the most since May 2012 after cutting its full-year revenue guidance.

Top 5 Electric Utility Stocks To Buy For 2015: ALLETE Inc (ALE)

ALLETE, Inc. (ALLETE) is an energy company. Minnkota Power Cooperative, Inc.( Minnesota Power) is an operating division of the Company. ALLETE operates in two business segments: Regulated Operations and Investments and Other. Regulated Operations includes its regulated utilities, Minnesota Power and Superior Water, Light and Power Company (SWL&P), as well as its investment in American Transmission Company LLC (ATC), a Wisconsin-based regulated utility that owns and maintains electric transmission assets in parts of Wisconsin, Michigan, Minnesota and Illinois. Investments and Other is comprised primarily of BNI Coal, Ltd (BNI Coal), its coal mining operations in North Dakota; ALLETE Properties, LLC and its subsidiaries (ALLETE Properties), its Florida real estate investment, and ALLETE Clean Energy. In July 2011, the Company incorporated new company, ALLETE Clean Energy.

Regulated Operations

Minnesota Power provides regulated utility electric servi ce in northeastern Minnesota to approximately 144,000 retail customers. Minnesota Power’s non-affiliated municipal customers consist of 16 municipalities in Minnesota and one private utility in Wisconsin. SWL&P, a wholly owned subsidiary of ALLETE, is also a private utility in Wisconsin and a customer of Minnesota Power. SWL&P provides regulated electric, natural gas and water service in northwestern Wisconsin to approximately 15,000 electric customers, 12,000 natural gas customers and 10,000 water customers. Its industrial customers are primarily in the taconite, paper, pulp and wood products and pipeline industries. The customers consist of five taconite producing facilities (two of which are owned by one company and are served under a single contract), one iron nugget plant, and four paper and pulp mills. During the year ended December 2011, its residential and commercial customers represented 20% of total regulated utility kilowatt-hour sales. In 2011, its municipal cust omers represented 7% of total regulated utility kilowatt-hou! r sales. The Company also enters into off-system sales with Other Power Suppliers.

The Company’s generation is primarily coal-fired, but also includes approximately 102 megawatts of hydro generation from ten hydro stations in Minnesota, approximately 107 megawatts of wind generation, and 73 megawatts of biomass co-fired generation. Purchased power is made up of long-term coal, wind and hydro power purchase agreements and market purchases. As of December 31, 2011, Minnesota Power had a coal inventory of 0.9 million tons. Minnesota Power entered into two long-term wind Power Purchase Agreements (PPAs) with an affiliate of NextEra Energy, Inc. to purchase the output from Oliver Wind I (50 megawatts) and Oliver Wind II (48 megawatts), wind facilities located near Center, North Dakota. Each agreement is for 25 years and provides for the purchase of all output from the facilities at fixed prices. The Company has a PPA with Manitoba Hydro that expires in April 2015. Under this agreement, Minnesota Power is purchasing 50 megawatts of capacity and the energy associated with that capacity. Minnesota Power has a separate PPA with Manitoba Hydro to purchase surplus energy from May 2011 through April 2022.

On May 19, 2011, Minnesota Power and Manitoba Hydro signed a long-term PPA. The PPA calls for Manitoba Hydro to sell 250 megawatts of capacity and energy to Minnesota Power for 15 years beginning in 2020 and requires construction of additional transmission capacity between Manitoba and the United States. On January 26, 2012, the Minnesota Public Utilities Commission (MPUC) approved this PPA with Manitoba Hydro. The Company has electric transmission and distribution lines of 500 kilovolts (eight miles), 345 kilovolts (29 miles), 250 kilovolts (465 miles), 230 kilovolts (632 miles), 161 kilovolts (43 miles), 138 kilovolts (128 miles), 115 kilovolts (1,221 miles) and less than 115 kilovolts (6,216 miles). Thye Company owns and o perates 164substations with a total capacity of 11,132 megav! oltampere! s. Some of its transmission and distribution lines interconnect with other utilities. Rainy River Energy, its wholly owned subsidiary, owns approximately 8% of American Transmission Company LLC (ATC), a Wisconsin-based utility that owns and maintains electric transmission assets in parts of Wisconsin, Michigan, Minnesota and Illinois. Hibbard is a 51 megttsa biomass/coal/natural gas facility located in Duluth, Minnesota. Minnesota Power holds franchises to construct and maintain an electric distribution and transmission system in 94 cities and towns located within its electric service territory. SWL&P holds 17 similar franchises for electric, natural gas and/or water systems in one city and 16 villages and towns within its service territory.

Investments and Other

BNI Coal is a supplier of lignite in North Dakota, producing about four million tons annually. Two electric generating cooperatives, Minnkota Power Cooperative, Inc. (Minnkota Power) and S quare Butte Electric Cooperative (Square Butte), consumes virtually all of BNI Coal’s production of lignite under cost-plus, fixed fee coal supply agreements extending through 2026. The mining process disturbs and reclaims between 200 and 250 acres per year. ALLETE Properties represents its Florida real estate investment. Its two major development projects are Town Center and Palm Coast Park. Another major project, Ormond Crossings is in the design and permitting stage. ALLETE Properties occasionally provides seller financing to certain qualified buyers. In June 2011, the Company ALLETE Clean Energy, a wholly owned subsidiary of ALLETE. ALLETE Clean Energy intends to market to electric utilities, cooperatives, municipalities, independent power marketers and end-users across North America through long-term PPAs. ALLETE Clean Energy focuses on developing or acquiring capital projects that create energy solutions through wind, solar, biomass, hydro, natural gas/liquids, shale resources, clean coal and other clean energy. As of Decembe! r 31, 201! 1, non-rate base generation consists of 31 megawatts of generation at Rapids Energy Center. In 2011, it sold 0.1 million Megawatt-hours of non-rate base generation. The Company has approximately 5,500 acres of land available-for-sale in Minnesota.

Advisors’ Opinion:

  • [By Marc Bastow]

    Utility holding company Allete (ALE) raised its quarterly dividend 3.2% to 49 cents per share, payable on Mar. 1 to shareholders of record as of Feb. 14.
    ALE Dividend Yield: 3.94%

  • [By Eric Volkman]

    ALLETE (NYSE: ALE  ) is continuing to be all in with its dividend. The company has declared its latest common stock distribution, which is to be $0.475 per share paid on Sept. 1 to shareholders of record as of Aug. 15. That amount matches the company’s previous two payouts, the most recent of which was dispensed at the beginning of June. Before that, the company was less generous by a cent and a half, handing out $0.46 per share.